Treating H. pylori Reduces the Risk for New Gastric Cancer

Helicobacter pylori eradication in patients with early gastric cancer reduced the risk for subsequent gastric cancer from 40.5/1000 person-years to 14.1/1000 person-years.

Helicobacter pylori infection is associated with gastric cancer, the second leading cause of cancer deaths globally. In a multicenter, open-label trial involving H. pylori–infected patients aged 20 to 79 with early gastric cancer (newly diagnosed or postresection), investigators assessed whether eradicating H. pylori would reduce the risk for new gastric tumors. The study was performed in Japan, where the usual treatment for early mucosal gastric cancer is endoscopic resection. Because only a small amount of mucosa is resected, patients are at risk for cancer at other gastric sites.

The 544 participants were randomized to receive H. pylori treatment (lansoprazole, amoxicillin, and clarithromycin for 1 week) or standard care but no antibioti…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine